A detailed history of Hanlon Investment Management, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Hanlon Investment Management, Inc. holds 1,360 shares of ABBV stock, worth $244,800. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,360
Previous 1,180 15.25%
Holding current value
$244,800
Previous $202,000 32.67%
% of portfolio
0.08%
Previous 0.06%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$163.84 - $199.33 $29,491 - $35,879
180 Added 15.25%
1,360 $268,000
Q2 2024

Aug 05, 2024

BUY
$154.79 - $180.76 $182,652 - $213,296
1,180 New
1,180 $202,000
Q1 2023

May 09, 2023

SELL
$144.61 - $166.54 $8,387 - $9,659
-58 Reduced 0.73%
7,932 $1.26 Million
Q4 2022

Jan 25, 2023

BUY
$138.31 - $165.87 $19,086 - $22,890
138 Added 1.76%
7,990 $0
Q3 2022

Nov 07, 2022

BUY
$134.21 - $153.93 $1.05 Million - $1.21 Million
7,852 New
7,852 $1.05 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Hanlon Investment Management, Inc. Portfolio

Follow Hanlon Investment Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hanlon Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hanlon Investment Management, Inc. with notifications on news.